SCD Data Gaps Analysis: What We Don't Know Is Hurting Patients
Analysis of critical data gaps in sickle cell disease management across Africa — missing prevalence data, outcome tracking failures, and the cost of flying blind.
Executive Summary
Despite being one of the most common genetic disorders globally, sickle cell disease suffers from profound data gaps that impede policy-making, resource allocation, and clinical care. This analysis identifies the most critical gaps: accurate prevalence data is unavailable for 70% of African countries, fewer than 5% of SCD deaths are captured in formal reporting systems, and treatment outcome data is available for less than 2% of African SCD patients. These gaps are not merely academic — they directly translate into preventable deaths, misallocated resources, and uninformed clinical guidelines.
Key Findings
Accurate SCD birth prevalence data is unavailable for 70% of African countries, with estimates based on extrapolation from small studies.
Fewer than 5% of SCD-related deaths in sub-Saharan Africa are captured in any formal vital registration or surveillance system.
Treatment outcome data is available for less than 2% of African SCD patients, creating a massive evidence gap for guidelines.
SCD research funding in Africa represents less than $3 per affected patient annually, compared to $1,200 for comparable disorders in high-income countries.
The Prevalence Data Gap
Accurate prevalence data is the foundation of public health planning. For SCD in Africa, estimates are largely extrapolated from sickle cell trait prevalence surveys combined with population models, carrying uncertainty intervals of 30% or more. Only a handful of countries have conducted population-based studies using gold-standard methods. A country estimating 100,000 patients but actually having 150,000 will systematically under-resource its program. Newborn screening provides the most accurate prevalence data but coverage remains very limited.
The Mortality Data Gap
Most African countries lack comprehensive vital registration, and existing systems frequently fail to capture SCD as a cause of death. The widely cited 50-80% under-5 mortality estimate is itself derived from modeling, not systematic surveillance. Without accurate mortality data, we cannot assess the true burden relative to other priorities, evaluate intervention impact, or hold programs accountable. Verbal autopsy studies suggest many SCD deaths are misattributed to malaria, pneumonia, or other infections.
The Treatment Outcome Gap
Clinical guidelines are primarily based on high-income country evidence. The African clinical context differs dramatically in co-morbidities, healthcare access, and available resources. For hydroxyurea, questions about optimal dosing in settings with limited lab monitoring, interactions with endemic infections, and long-term safety in genetically distinct populations remain incompletely answered. Patient registries and tracking systems generate the real-world evidence needed to fill these gaps over time.
Closing the Gaps
Addressing gaps requires expanding newborn screening for accurate prevalence data and patient identification. Strengthening vital registration and training workers to certify SCD deaths improves mortality data. Deploying digital tracking generates longitudinal clinical data for outcome analysis. Increasing research funding for African-based SCD studies — currently at a fraction of comparable diseases — is essential for building the context-appropriate evidence base.
Download the full report
Enter your email to receive the complete “SCD Data Gaps Analysis: What We Don't Know Is Hurting Patients” report as a downloadable PDF.